Cevidoplenib
CAS: 1703788-21-9
Ref. 3D-DTC78821
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Product Information
Cevidoplenib is a small molecule inhibitor of the receptor tyrosine kinase RET, which is associated with a variety of cancers. It binds to the active site of RET, preventing activation and causing RET to be degraded. Cevidoplenib inhibits the phosphorylation of tyrosine residues on RET, thereby blocking RET-mediated signaling cascades. This inhibition leads to decreased cell proliferation and survival in vitro and in vivo. Cevidoplenib is currently in phase II clinical trials for patients with thyroid cancer or medullary thyroid carcinoma.
Chemical properties
Technical inquiry about: 3D-DTC78821 Cevidoplenib
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
